WebAug 12, 2024 · To Use DOACs in Obesity or Not? Direct-acting oral anticoagulants (DOACs; also called NOACs – novel oral anticoagulants) are an increasingly popular alternative to warfarin. Meanwhile, the number of obese patients requiring anticoagulation is also increasing. WebMay 22, 2024 · The efficacy and safety of DOACs in patients with high BW/BMI has not yet been elucidated by randomized trials; however, 2016 international guidelines suggest avoiding their use in patients with a BW >120 kg or BMI >40 kg/m 2.Since 2016, several studies have been published examining use of DOACs in this patient population.
Which anticoagulant is best for obese patients?
WebA total of 10 studies including, 89,494 morbidly obese patients with NVAF on oral anticoagulation therapy (45,427 on DOACs vs. 44,067 on warfarin) were included in the … WebMay 16, 2024 · Abstract Relatively little is known about the influence of extreme body weight on the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs … scripted video
Direct Oral Anticoagulants in Obese Patients with Venous ...
WebApr 13, 2024 · Based on eligibility criteria, the dataset of morbidly obese patients on DOACs was extracted from EHRs, pre-processed and analysed considering the access … WebMar 30, 2024 · Background Direct oral anticoagulants (DOACs) have become favorable choices for anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non-inferiority or superiority to warfarin. DOACs are currently not recommended in patients with a body weight ≥ 120 kg or body mass index ≥ 40 kg/m2 due to limited data … Web• Newer evidence indicates that in patients with nonvalvular AF, DOACs compared to warfarin were associated with better safety and effectiveness across all BMI categories, including underweight and morbidly obese patients 5,6. • The efficacy and safety of edoxaban in overweight patients with BMI 30 to >40kg/m2 scripted variables corrupted upon dayz